Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 10M | 10M | 7M | 0 |
| Gross Profit | 0 | 464K | 1M | -1M | -157K |
| Operating Income | -6K | -2M | -260K | -3M | -701K |
| EBITDA | 162K | -3M | -23K | -4M | 161K |
| Net Income | -13K | -3M | -301K | -4M | -313K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SFLMaven Corp. (SFLM) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +100.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 0.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SFLM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SFLM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SFLM Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SFLM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$313.0K
+93.0% YoY
Free Cash Flow
-$133.8K
+73.8% YoY
Revenue Growth
-100.0%
EPS Growth
+100.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 10M | 10M | 7M | 0 |
| Gross Profit | 0 | 464K | 1M | -1M | -157K |
| Operating Income | -6K | -2M | -260K | -3M | -701K |
| EBITDA | 162K | -3M | -23K | -4M | 161K |
| Net Income | -13K | -3M | -301K | -4M | -313K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 265K | 5K | 0 |
| Total Assets | 0 | 50K | 2M | 838K | 161K |
| Total Liabilities | 102K | 2M | 2M | 3M | 612K |
| Shareholder Equity | -2M | -2M | -207K | -2M | -451K |
| Total Debt | 102K | 2M | 45K | 3M | 264K |
| Net Debt | 102K | 2M | -220K | 505K | 264K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
134K
+73.8% YoY
Capital Expenditures
0
Free Cash Flow
134K
+73.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
0.8%
Debt / Equity
-0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.